

Taniguchi N.					
Isono K, Nemoto K, Li Y, Takada Y, Suzuki R, Katsuki M, <u>Nakagawara A</u> , Koseki H.	Overlapping roles for homeodomain-interacting protein kinases Hipk1 and Hipk2 in the mediation of cell growth in response to morphogenetic and genotoxic signals.	Moll. Cell. Biol.	26(7)	2758-2771	2006
Machida T, Fujita T, Oo M L, Ohira M, Isogai E, Mihara M, Hirato J, Tomotsune D, Hirata T, Fujimori M, Adachi W, <u>Nakagawara A</u> .	Increased expression of pro-apoptotic BMCC1, a novel gene with the BNIP2 and Cdc42GAP homology (BCH) domain, is associated with favorable prognosis in human neuroblastomas.	Oncogene	in press		
Niizuma H, Nakamura Y, Ozaki T, Ohira M, Isogai E, Kageyama H, Imaizumi M, <u>Nakagawara A</u> .	Bcl-2 is a key regulator for the retinoic acid-induced apoptotic cell death in neuroblastoma.	Oncogene	in press		
Chen H, Suzuki M, Nakamura Y, Ohira M, Suenaga Y, Ando S, Iida T, Nakajima T, <u>Nakagawara A</u> , Kimura H.	Aberrant methylation of RASGRF2 and RASSF1A in human non-small cell lung cancer.	Oncol. Rep.	in press		

研究成果の刊行に関する一覧表

分担研究者：尾崎 俊文

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kramer S, <u>Ozaki T</u> , Miyazaki K, Kato C, Hanamoto T, Nakagawara A.	Protein stability and function of p73 are modulated by a physical interaction with RanBPM in mammalian cultured cells.	Oncogene	24(5)	938-944	2005
Lin L, <u>Ozaki T</u> , Takada Y, Kageyama H, Nakamura Y, Hata A, Zhang J-H, Simonds W, Nakagawara A, Koseki H.	Topors, a p53 and topoisomerase I-binding RING finger protein, is a co-activator of p53 in growth suppression induced by DNA damage.	Oncogene	24(21)	3385-3396	2005
<u>Ozaki T</u> , Hosoda M, Miyazaki K, Hayashi S, Watanabe K, Nakagawa T, Nakagawara A.	Functional implication of p73 protein stability in neuronal cell survival and death.	Cancer Lett.	228(1-2)	29-35	2005
Hanamoto T, <u>Ozaki T</u> , Furuya K, Hosoda M, Hayashi S, Nakanishi M, Yamamoto H, Kikuchi H, Todo S, Nakagawara A.	Identification of protein kinase A catalytic subunit beta as a novel binding partner of p73 and regulation of p73 function.	J. Biol. Chem.	280(17)	16665-16675	2005
Aoyama M, <u>Ozaki T</u> , Inuzuka H, Tomotsune D, Hirato J, Okamoto Y, Tokita H, Ohira M, Nakagawara A.	LMO3 interacts with neuronal transcription factor, HEN2, and acts as an oncogene in neuroblastoma.	Cancer Res.	65(1)	4587-4597	2005
<u>Ozaki T</u> , Nakagawara A.	p73, a sophisticated p53 family member in the cancer world.	Cancer Sci.	96(11)	729-737	2005
Hosoda M, <u>Ozaki T</u> , Miyazaki K, Hayashi S, Furuya K, Watanabe K, Nakagawa T, Hanamoto T, Todo S, Nakagawara A.	UFD2a mediates the proteasomal turnover of p73 without promoting p73 ubiquitination.	Oncogene	24(48)	7156-7169	2005
Niizuma H, Nakamura Y, <u>Ozaki T</u> , Ohira M, Isogai E, Kageyama H, Imaizumi M, Nakagawara A.	Bcl-2 is a key regulator for the retinoic acid-induced apoptotic cell death in neuroblastoma.	Oncogene	in press		

研究成果の刊行に関する一覧表

分担研究者：竹永 啓三

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kato C, Kojima T, Komaki M, Mimori K, Duarte WR, <u>Takenaga K</u> , Ishikawa I.	S100A4 inhibition by RNAi up-regulates osteoblast related genes in periodontal ligament cells.	Biochem. Biophys. Res. Commun.	326(1)	147-153	2005
Kondo N, Ichimiya S, Tamura Y, Tonooka A, Koshiba S, Torigoe T, Kamiguchi K, <u>Takenaga K</u> , Sato N.	A calcium binding protein, S100A4, mediates T cell dependent cytotoxicity as a transformation-associated antigen.	Microbiol. Immunol.	49(1)	49-56	2005
Kozlova EN, <u>Takenaga K</u> .	A procedure for culturing astrocytes from white matter and the application of the siRNA technique for silencing the expression of their specific marker, S100A4.	Brain Res. Brain Res. Protoc.	15(2)	59-65	2005
Koshikawa N, <u>Takenaga K</u> .	Hypoxia-regulated expression of attenuated diphtheria toxin A fused with hypoxia-inducible factor-1 α oxygen-dependent degradation domain preferentially induces apoptosis of hypoxic cells in solid tumor.	Cancer Res.	65(24)	11622-1630	2005
Koshikawa N, Maejima C, Miyazaki K, Nakagawara A, <u>Takenaga K</u> .	Hypoxia selects for high-metastatic Lewis lung carcinoma cells overexpressing Mcl-1 and exhibiting reduced apoptotic potential in solid tumors.	Oncogene	25(6)	917-928	2006
<u>Takenaga K</u> , Kozlova EN.	Role of intracellular S100A4 for migration of rat astrocytes.	Glia	53(3)	313-321	2006
Fang Z, Forslund N, <u>Takenaga K</u> , Lukanidin E, Kozlova EN.	Sensory neurite outgrowth on white matter astrocytes is influenced by intracellular and extracellular S100A4 protein.	J. Neurosci. Res.	in press		
Fang Z, Duthoit N, Wicher G, Kallskog O, Ambartsumian N, Lukanidin E, <u>Takenaga K</u> , Kozlova EN.	Intracellular calcium-binding protein S100A4 influences injury-induced migration of white matter astrocytes.	Acta. Neuropathol.	in press		

研究成果の刊行に関する一覧表

分担研究者：古関 明彦

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Isono K, Mizutani-Koseki Y, Komori T, Schmidt-Zachmann M.S, <u>Koseki H.</u>	Mammalian Polycomb-mediated repression of <i>Hox</i> genes requires the essential spliceosomal protein sf3b1.	Gene Dev.	19(5)	536-541	2005
Lin L, Ozaki T, Takada Y, Kageyama H, Nakamura Y, Hata A, Zhang J.H, Simonds W, Nakagawara A, <u>Koseki H.</u>	Topors, a p53 and topoisomerase I-binding RING finger protein, is a co-activator of p53 in growth suppression induced by DNA damage.	Oncogene	24(21)	3385-3396	2005
Shin T, Yoshimura K, Shin T, Crafton EB, Tsuchiya H, Housseau F, <u>Koseki H.</u> , Schulick RD, Chen L, Pardoll DM.	In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses.	J. Exp. Med.	201(10)	1531-1541	2005
Inoue K, Wakao H, Ogonuki N, Miki H, Seino K, Nambu-Wakao R, Noda S, Miyoshi H, <u>Koseki H.</u> , Taniguchi M, Ogura A.	Generation of cloned mice by direct nuclear transfer from natural killer T cells.	Curr. Biol.	15(12)	1114-1118	2005
Baba T, Shimizu T, Suzuki YI, Ogawara M, Isono KI, <u>Koseki H.</u> , Kurosawa H, Shirasawa T.	Estrogen, insulin, and dietary signals cooperatively regulate longevity signals to enhance resistance to oxidative stress in mice.	J. Biol. Chem.	280(16)	16417-16426	2005
Oike Y, Akao M, Yasunaga K, Yamauchi T, Morisada T, Ito Y, Urano T, Kimura Y, Kubota Y, Maekawa H, Miyamoto T, Miyata K, Matsumoto SI, Sakai J, Nakagata N, Takeya M, <u>Koseki H.</u> , Ogawa Y, Kadowaki T, Suda T.	Angiopoietin-related growth factor antagonizes obesity and insulin resistance.	Nat. Med.	11(4)	400-408	2005
Isono K, Fujimura Y, Shinga J, Yamaki M, O-Wang J, Takihara Y, Murahashi Y, Takada Y, Mizutani-Koseki Y, <u>Koseki H.</u>	Mammalian polyhomeotic homologues Phc2 and Phc1 act in synergy to mediate Polycomb-repression of <i>Hox</i> genes.	Mol. Cell. Biol.	25(15)	6694-706	2005

Masuda K, Ouchida R, Takeuchi A, Saito Takashi, <u>Koseki H</u> , Kawamura K, Tagawa M, Tokuhisa T, Azuma T, O-Wang J.	JDNA polymerase {theta} contributes to the generation of C/G mutations during somatic hypermutation of Ig genes.	Proc. Natl. Acad. Sci. USA	102(39)	13986-13991	2005
Nakajima M, Ogawa M, Shimoda Y, Hiraoka S, Iida M, <u>Koseki H</u> , Shirasawa T, Furukawa K.	Presenilin-1 controls the growth and differentiation of endothelial progenitor cells through its beta-catenin-binding region.	Cell Biol. Int.	30(3)	239-243	2006
Isono K, Nemoto K, LiY, Takada Y, Suzuki R, Katsuki M, Nakagawara A, <u>Koseki H</u> .	Overlapping roles for homeodomain-interacting protein kinases Hipk1 and Hipk2 in the mediation of cell growth in response to morphogenetic and genotoxic signals.	Mol. Cell. Biol.	in press		
Takano-Maruyama M, Hase K, Fukamachi H, Kato Y, <u>Koseki H</u> , Ohno H.	Foxl1-deficient mice exhibit aberrant epithelial cell positioning due to dysregulated EphB/EphrinB expression in the small intestine.	Am. J. Physiol. Gastrointest. Liver Physiol.	in press		
Blewitt ME, Vickaryous NK, Paldi A, <u>Koseki H</u> , Whitelaw E.	Dynamic reprogramming of DNA methylation at an epigenetically sensitive allele in mice.	PLoS Genetics	in press		
Lee T, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM, Chevalier B, Johnstone SE, Cole MF, Isono K, <u>Koseki H</u> , Fuchikami T, Abe K, Murray HL, Zucker JP, Yuan B, Bell GW, Herbolsheimer E, Hannett NM, Sun K, Odom DT, Volkert TL, Bartel DP, Melton DA, Gifford DK, Jaenisch R, Young RA.	Control of Developmental Regulators by Polycomb in Human Embryonic Stem Cells.	Cell	in press		

研究成果の刊行物・別刷

Molecular and Developmental Biology of Neuroblastoma

Akira Nakagawara

Contents

5.1	Neural Crest Development and Neuroblastoma	41
5.1.1	Genes of Neural Development and Molecular Targets of Neuroblastoma	41
5.1.1.1	Bone Morphogenetic Proteins	43
5.1.1.2	<i>MASH1/hASH1</i>	43
5.1.1.3	Phox2a and Phox2b	44
5.1.1.4	Id	44
5.1.1.5	<i>MYCN</i>	45
5.2	Molecular Bases of Differentiation and Programmed Cell Death	45
5.2.1	Molecular Aspect of Spontaneous Regression	45
5.2.2	Neurotrophic Factors and Their Receptors	46
5.2.2.1	Neurotrophins and Their Receptors in Neuroblastoma	46
5.2.2.2	Neurotrophin Signaling in Neuroblastoma	46
5.2.2.3	GDNF Family Receptors	48
5.2.2.4	Other Factors and Receptors	48
5.2.3	Functional Role of p53 Family Genes	48
5.2.4	Apoptotic Signals in Neuroblastoma	50
5.3	Conclusions	50
	References	51

5.1 Neural Crest Development and Neuroblastoma

Cancer has its own face reflecting the characteristics of the tissue from which it is derived. This can be demonstrated by histopathologic examination, by immunohistochemistry, and/or by in situ hybridization. Recent advances in molecular biology and genetics have also revealed that these morphological distinctions among cancers are associated with differences in gene expression profiles within tumor cell and stromal cell components. Furthermore, the patterns of gene expression unique for each cancer are dictated by genetic abnormalities which have occurred in progenitors of the specific developmental lineage. Neuroblastoma originates from the sympathoadrenal lineage, and its biology is closely related to that of normal sympathetic neurons. In this chapter, the molecular and cellular bases for the genesis and biology of neuroblastoma are summarized.

5.1.1 Genes of Neural Development and Molecular Targets of Neuroblastoma

During neural development, neural crest cells migrate and differentiate into several cell lineages, e.g., melanocytes, sensory neurons, enteric ganglion cells, and sympathetic neurons (Fig. 5.1). The first signaling molecules which trigger crest cells to differentiate or migrate are bone morphogenetic proteins (BMPs) and their receptors (Huber et al. 2002). The commitment to differentiate into sympathetic neurons is associated with the transient expression of (a) basic helix-loop-helix transcription factors, e.g., *MASH1* (a proneural gene homologous to *drosophila achaete-*




Figure 5.1

Neuroblastoma originates from the sympathoadrenal lineage of neural crest. The bone morphogenetic protein (BMP) signals may be important at the early stage of differentiation of neural crest cells. *MASH1* (*hASH1*) may function as one of the key transcription factors which define the direction of differentiation to sympathetic neurons. The other important nuclear factors, e.g., *Phox2a*, *Phox2b*, *HuD*, *MYCN*, *Id2*, and *p73*, may also be involved in the cell-fate determination. Some of those genes are often upregulated or amplified in aggressive neuroblastomas (Nakagawara 2004). At the stage of terminal differentiation of sympathetic neurons followed by programmed cell death, the signals through neuronal tyrosine kinase receptors, e.g., *Ret*, *TrkB*, *TrkC*, and *TrkA*, are necessary sequentially and/or in a form of crosstalk. The many genes involved in regulation of neuronal terminal differentiation or programmed cell death are often expressed at high levels in favorable neuroblastomas


scute), *HES1*, *MYCN*, *HIF1 α* and *HuD*, (b) homeobox genes, e.g., *Phox2a* and *Phox2b*, and (c) *p73* (a family member of the tumor suppressor gene *p53*; Nakagawara 2004). Several lines of investigation support the importance of these genes. *MASH1* null mice lack sympathetic ganglion cells (Guillemot et al. 1993). Notch signaling, through its intracellular domain translocation into the nucleus, stimulates the transcriptional activation of the *HES1* and *HES5* genes whose products in turn inhibit transcription of the *MASH1* gene (Radtke and Raj 2003). *MYCN* is indispensable for the normal neural development. It induces *Id2* which is a negative regulator of *HES1* and *pRb*, a retinoblastoma suppressor (Lasorella et al. 2000). *p73* knockout mice also show abnormalities in cell survival in both the nervous and immune systems (Yang et al. 2000). Gene targeting of *HIF2 α* dis-

turbs the catecholamine metabolism in sympathetic neurons (Tian et al. 1998). All these genes regulate each other in an orchestrated manner to drive the correct differentiation of neural crest cells into sympathetic neurons.

Further downstream, terminal differentiation to mature sympathetic cells is strongly regulated by the signaling of neurotrophin family members and their receptors (Nakagawara 2001, 2004). In addition, other genetic aberrations associated with neuroblastoma have been mapped to specific genomic regions or genes well known to be important in regulating the normal development of neurons (Nakagawara 2001, 2004). It seems obvious that a relationship should exist between the genetic or biological targets of neuroblastoma and the key molecules involved in the normal development of neural crest cells.

Figure 5.2

Hedgehog-Gli signaling in neural development and tumorigenesis. Sonic hedgehog (Hh) signaling activates Gli transcription factors which then induce the target genes important for regulating neural differentiation as well as neuronal tumorigenesis. They include *MYCN*, *cyclin D1*, *IGF2*, and *PDGFR α* , all of which are known to be players characterizing neuroblastoma biology. *T* bars show inhibitory interactions. Arrows show positive interactions



5.1.1.1 Bone Morphogenetic Proteins

Bone morphogenetic proteins (BMPs), members of the transforming growth factor- β (TGF- β) superfamily, may be the first signal that defines the early phase of differentiation and migration of neural crest cells during development (Oppenheim 1991). The ligand-dependent activation of BMP receptors transduces its signal into the nucleus through the sequential activation of Smad signaling molecules by phosphorylation. Although the role of BMPs in neuroblastoma has long been elusive, Nakamura et al. (2003) have recently reported that SH-SY5Y and RTBM1 neuroblastoma cell lines are responsive to BMP2 leading to growth arrest and differentiation. Of interest, BMP treatment also induces the downregulation of p53 family members including p53 and p73, as well as their target gene, *p21^{WAF1}*. In contrast, a similar cyclin-dependent kinase inhibitor, *p27^{KIP1}*, is markedly induced at the protein level by downregulation of Skp2, a component of its E3 ubiquitin ligase complex. BMP is also a direct transcriptional target of retinoic acid which induces neuroblastoma differentiation (see Chap. 15; Rodriguez-Leon et al. 1999). The DAN fam-

ily members are inhibitors of BMP, and are also expressed in neuroblastomas (Enomoto et al. 1994). The DAN gene itself, which is mapped to chromosome 1p36, is a transcriptional target of BMP (Nakamura et al. 2003; Shinbo et al. 2002), suggesting that the BMP signaling network may be important in the differentiation and survival of neuroblastoma (Nakamura et al. 2003). The role of other important signals which function during neuronal development, including Sonic Hedgehog (Shh) and Wnt, is less well known in neuroblastoma. Interestingly, the Shh downstream signaling molecule, Gli, can transactivate *MYCN* and *cyclin D1* (Altaba et al. 2004) (Fig. 5.2).

5.1.1.2 MASH1/hASH1

Achaete-Scute homolog-1 (*MASH1* in rodents and *hASH1* in humans) is a basic helix-loop-helix transcription factor which plays an important role in the early development of neural and neuroendocrine progenitor cells (Ball 2004). Helix-loop-helix proteins include achaete-scute homologs, E proteins, *MYCN*, *Math*, *NeuroD*, *neurogenin*, *Id*, and *HES*. Targeted disruption of *MASH1* in mice has led to the absence of




Figure 5.3

Notch signaling transactivates gene expression to induce neuronal differentiation. Binding of the ligand delta to its receptor notch triggers intramembrane proteolytic cleavage by γ -secretase. This results in the release of the notch intracellular domain (NICD), which then translocates to the nucleus where it associates with the CSL family of DNA binding proteins and transactivates gene expression. The target genes include *HES1*, *MATH1*, *NF- κ B*, *cyclin D1*, *p21^{WAF1}*, and *neurogenin*. *HES1* then inhibits transactivation of *MASH1* (*hASH1*)

sympathetic neurons, suggesting the important role of *MASH1* in sympathetic differentiation (Guillemot et al. 1993). *MASH1* is transiently induced during neural development to promote neuronal cell differentiation; however, high *hASH1* expression persists in neuroblastoma tumors and cell lines (Soderholm et al. 1999; Ichimiya et al. 2001). Retinoic acid treatment decreases the expression of *hASH1* and induces neurite extension (Ichimiya et al. 2001). *hASH1* also directly represses the expression of *PACE4*, a mammalian subtilin-like proprotein convertase that activates TGF- β -related proteins (e.g., BMPs) in neuro-

blastoma cell lines (Yoshida et al. 2001). The Notch signaling pathway also plays a key role during neuronal development (Axelson 2004). One of the important regulators of *hASH1* is a basic HLH protein, *HES1* (Fig. 5.3). *HES1* is regulated, at least in part, by Notch signaling and is induced at the transcription level. *HES1* directly binds to the promoter of *hASH1* and inhibits its transcriptional activation. A constitutively active form of Notch could block neurite extension during the induced differentiation of human neuroblastoma cells, possibly by inhibiting *hASH1* through the induction of *HES1* (Radtke and Raj 2003).

5.1.1.3 Phox2a and Phox2b


Phox2a and Phox2b are paired-like homeodomain transcription factors with complete conservation in their homeodomain. They are specifically expressed in noradrenergic neurons and activate the tyrosine hydroxylase and dopamine- β -hydroxylase genes (Schneider et al. 1999; Stanke et al. 1999; Ernberger 2000). While the expression of Phox2a is regulated by *MASH1*, Phox2b is not (Lo et al. 1999) (Fig. 5.4). The genetic disruption of either Phox2a or Phox2b gene demonstrated that both genes are essential for the development of autonomic neural crest derivatives (Morin et al. 1997; Pattyn et al. 1999). Interestingly, Trochet et al. (2004) reported that the Phox2b gene was mutated in a family case of neuroblastoma and in a neuroblastoma patient with Hirschsprung's disease.

5.1.1.4 Id

Id proteins generally function as inhibitors of differentiation and as positive regulators of proliferation in neuronal development (Lavarone and Lasorella 2004). Id is a protein with the helix-loop-helix domain without a basic region and forms heterodimers with bHLH proteins, e.g., *MASH1* and *HES1* to inhibit their transactivation function (Massari and Murre 2000). In pediatric cancers, *MYC* oncoproteins and EWS-Ets fusion proteins are targeted to induce Id2 which in turn inhibits Rb and other target proteins including bHLH proteins, Ets and Pax. In neuroblastoma, *MYCN* has been shown to induce Id2 which stimulates cell proliferation by inhibiting Rb function (Lasorella et al. 2000).

Figure 5.4

Regulatory network controlling sympathetic neuron development. BMP2 and BMP4 are required for the expression of *MASH1* and *Phox2b*. *HES1* induced by notch signaling inhibits expression of *MASH1*. *MASH1* and *Phox2b* are genetically upstream of *Phox2a*, and *Phox2b* is genetically upstream of *Gata3*. Expression of tyrosine hydroxylase (TH) and dopamine- β -hydroxylase (DBH) depends on *MASH1*, *Phox2b*, and *Gata3*. Cyclic AMP also controls expression of TH and DBH. *Phox2a* and *Phox2b* may affect induction or maintenance of *MASH1* expression. *MASH1*, *Phox2a*, and *Phox2b* regulate the downstream neurogenic program, leading to terminal differentiation of sympathetic neurons by inducing the genes, e.g., *Trks*, *NF160*, *peripherin*, and *SCG10*.



5.1.1.5 MYCN

MYCN is a member of the group of *MYC*-box genes, and its product is a bHLH protein (Schwab et al. 2003). *MYCN* is transiently expressed during normal neural development and defines the direction of neuronal differentiation. *MYCN* is frequently amplified in advanced-stage neuroblastoma (Schwab et al. 1983, 1984; Brodeur et al. 1984; Seeger et al. 1985), and the biology of high-risk neuroblastoma is influenced by the subsequent overexpression of *MYCN* oncoprotein and its targets including telomerase and those functioning in ribosome biogenesis and protein synthesis (Mac et al. 2000; Boon et al. 2001).

5.2 Molecular Bases of Differentiation and Programmed Cell Death

5.2.1 Molecular Aspect of Spontaneous Regression

It is well known that some subsets of neuroblastoma can regress spontaneously. One of the most important hints to understand the mechanism of spontaneous regression is age of the patient at the onset of neuroblastoma. Regression rarely occurs when the tumor is found in patients over 1 year of age. The dramatic regression of the stage 4s tumor after its rapid growth usually occurs within 6 months after birth; therefore, it is plausible that epigenetic regulations, timed with the development of sympathetic neurons, might also control neuroblastoma regression. It is well known that massive death of sympathetic neurons is induced during the perinatal period – a process called developmentally regulated neuronal programmed cell death following deprivation of tar-

get tissue-derived neurotrophins (Oppenheim 1991). This same death mechanism appears to be conserved in primary neuroblastomas found in infants, leading to the induction of their spontaneous regression (Nakagawara 1998b).

5.2.2 Neurotrophic Factors and Their Receptors

5.2.2.1 Neurotrophins and Their Receptors in Neuroblastoma

The neurotrophin family of growth factors consists of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5; Huang and Reichardt 2003). The corresponding high-affinity neurotrophin receptors with tyrosine kinase activity have been identified as TrkA, TrkB, and TrkC (Snider 1994) (Fig. 5.5 a, b). TrkA is a preferred receptor for NGF, TrkB for BDNF and NT-4/5, and TrkC for NT-3. All of the neurotrophins also bind similarly to a lower-affinity neurotrophin receptor $p75^{NTR}$, a member of the tumor necrosis factor receptor (TNFR)/Fas family (Snider 1994). The targeted disruption of neurotrophins and their receptors has demonstrated that NGF/TrkA signaling supports the survival and differentiation of sympathetic and sensory neurons responsive to temperature and pain, while BDNF/TrkB, NT-4/TrkB, and NT-3/TrkC signaling supports those of sensory neurons responsive to tactile stimuli and motor and sensory neurons responsive to limb movement and position, respectively (Klein 1994). These results suggest that neural development and maintenance of the neural network are spatiotemporally controlled by neurotrophin signaling with or without some redundancy in both peripheral and central nervous systems.

In neuroblastoma, high levels of TrkA are expressed in subsets of tumors with good prognosis, often showing spontaneous regression (Nakagawara et al. 1992, 1993; Suzuki et al. 1993; Kogner et al. 1993). Such tumors usually occur in patients under 1 year of age, and their DNA ploidy is aneuploid. A very limited amount of NGF may be supplied from stromal cells, e.g., Schwannian cells and fibroblasts, which at least partly regulate the differentiation and pro-

grammed cell death of neuroblastoma cells (Nakagawara 1998a). On the other hand, TrkA expression is strongly downregulated in tumors with aggressive behavior that usually possess amplification of the *MYCN* oncogene and allelic loss of chromosome 1p36 (Nakagawara et al. 1992, 1993). TrkB is preferentially expressed in aggressive neuroblastomas together with its preferred ligands BDNF and NT-4/5 which stimulate in an autocrine/paracrine manner, conferring an enhanced malignant phenotype to the tumor cells (Nakagawara et al. 1994; Matsumoto et al. 1995). TrkC is expressed in favorable neuroblastomas at variable levels (Yamashiro et al. 1996), but its preferred ligand, NT-3, is nearly undetectable by RT-PCR in primary neuroblastomas (Nakagawara 1998a); thus, in regressing neuroblastomas, tumor cells expressing the TrkA receptor may be dependent on a limited amount of NGF supplied from stromal cell. In the presence of NGF the cells mature, whereas they will die in the absence of this ligand (Nakagawara 1998a,b); however, in clinically aggressive neuroblastomas, the TrkA is downregulated and the downstream signaling cascades are disturbed, and these cells utilize the BDNF or NT-4/TrkB autocrine system for efficient growth. Neurotrophin signaling may also regulate tumor metastasis (Matsumoto et al. 1995), proliferation (Matsumoto et al. 1995), and angiogenesis (Canete et al. 2000). The role of $p75^{NTR}$ in neuroblastoma is unclear. The $p75^{NTR}$ receptor is expressed in both neuroblastoma cell lines (Azar et al. 1990) and primary neuroblastomas (Nakagawara et al. 1993). Interestingly, the expression levels of $p75^{NTR}$ mRNA are significantly higher in favorable neuroblastomas (stages 1, 2 and 4s) as compared with the advanced stage tumors, especially those with *MYCN* amplification (Nakagawara et al. 1993).

5.2.2.2 Neurotrophin Signaling in Neuroblastoma

In a rat pheochromocytoma cell line PC12, differentiation signals by NGF may be mediated through the tyrosine phosphorylation of the Trk receptor and through the subsequent activation of Shc/Grb2/SOS, Ras, Raf, MEK, and ERKs, while survival signals in the same cells may be transduced through the direct





Figure 5.5 a, b

Neurotrophins and their receptors. a TrkA is a preferred high-affinity receptor for NGF, TrkB for BDNF, and NT-4/5, and TrkC for NT-3. All of the neurotrophins also bind similarly to a lower affinity neurotrophin receptor p75^{NTR}. b The structures of neurotrophin family receptors. The extracellular domains of TrkA, TrkB, and TrkC have high structural similarity. The intracellular domain of Trks possesses tyrosine kinase activity. TrkB and TrkC receptors have truncated forms which lack the tyrosine kinase domain. The low-affinity receptor, p75^{NTR}, has a short intracellular region containing the death domain, and belongs to the Fas/TNFR family of the receptors.



activation of PI3-kinase which in turn activates downstream molecules, e.g., Akt and Bad (Klesse and Parada 1999). On the other hand, in normal sympathetic neurons, the activation of PI3-kinase is mediated not by the tyrosine phosphorylation of the receptor but by the Ras activation which promotes neuronal survival, suggesting that the Trk intracellular signaling pathway might be deregulated in cancer cells. This is also the case in neuroblastoma. In the neuroblastoma cell lines with a single copy of *MYCN*, NGF can induce differentiation when exogenous TrkA is overexpressed (Eggert et al. 2000). In the cell lines with *MYCN* amplification, however, the NGF-stimulated TrkA receptors which were overexpressed cannot normally activate downstream signaling molecules, resulting in unresponsiveness to the ligand. Furthermore, it is surprising that BDNF/TrkB signaling appears to be functioning in the same cells by promoting survival (Nakagawara et al. 1994; Hishiki et al. 1998), although the signaling pathway might be different from that of sympathetic neurons (Klesse and Parada 1999).

5.2.2.3 GDNF Family Receptors

Neurotrophic factors of the glial cell line-derived neurotrophic factor (GDNF) family, which include GDNF, artemin and neurturin, are secreted by neuroblastoma cells as well as stromal cells and activate their receptor complex composed of Ret tyrosine kinase and the GFR α co-receptors expressed in neuroblastoma cells (Hishiki et al. 1998; Ichikawa et al. 2004). In contrast to NGF/TrkA and BDNF/TrkB, however, the GDNF/Ret/GFR α autocrine system is functioning in both favorable and unfavorable neuroblastomas to enhance the survival and differentiation of tumor cells (Hishiki et al. 1998).

5.2.2.4 Other Factors and Receptors

Neuroblastoma cells express other growth factors and receptors. Both pleiotrophin (PTN) and midkine (MK) are factors in the same family with neurotrophic function (Kadomatsu et al. 1990; Li et al. 1990; Kadomatsu and Muramatsu 2004). PTN is expressed significantly at high levels in favorable neuroblas-

tomas, while MK is highly expressed in almost all neuroblastomas with a tendency to be expressed at high levels in tumors in advanced stages (Nakagawara et al. 1995). Neuroblastoma also expresses many other receptors, e.g., fibroblast growth factor receptor (FGFR; Schweigerer et al. 1991), insulin-like growth factor (IGFR; El-Badry et al. 1991), DCC (deleted in colon cancer) (Reale et al. 1996), and neuronal leucine-rich repeat receptors (NLRs; Hamano et al. 2004), as well as a novel plasma membrane enzyme ECEL1, which is significantly highly expressed in favorable neuroblastomas (Kawamoto et al. 2003). The biological significance of these factors and receptors in neuroblastoma are not currently known.

5.2.3 Functional Role of p53 Family Genes

Recent lines of evidence suggest that both the p53 tumor suppressor protein and its related protein p73 are involved in the induction of programmed cell death and growth arrest in neuronal cells (Pozniak et al. 2000). p73 is a recently identified candidate tumor suppressor gene mapped to chromosome 1p36.2, a frequently deleted region in many human cancers including neuroblastoma and oligodendroglioma (Ichimiya et al. 1999; Billon et al. 2004). In cultured neonatal sympathetic neurons, p53 protein levels are increased in response to NGF withdrawal as well as p75^{NTR} activation, and it functions downstream of c-Jun NH₂-terminal kinase (JNK) and upstream of Bax to induce apoptosis (Aloyz et al. 1998) (Fig. 5.6). Indeed, in p53^{-/-} mice, naturally occurring sympathetic neuron death is inhibited. Pozniak et al. (2000) have also reported that p73 is primarily present in developing neurons as Δ Np73, an NH₂-terminally truncated isoform, whose level is decreased when sympathetic neurons undergo apoptosis after NGF withdrawal, and that p53 becomes activated to be pro-apoptotic. In contrast to the truncated form of p73, full-length p73 has induced neuronal differentiation in a mouse neuroblastoma cell line N1E115 (Laurenzi et al. 2000). These data suggest that the neuronal apoptosis induced by NGF withdrawal is at least partly regulated by a reciprocal balance between levels of pro-apoptotic p53 and anti-apoptotic Δ Np73.

Figure 5.6

A model of signaling pathway for survival and death in sympathetic neurons regulated by NGF. NGF depletion may induce activation of JNK/p53 pathway which could be modified by p73/ Δ Np73 regulatory system. p75^{NTR} activation, which sends signals of both survival and death, may also regulate downstream p53/p73/ Δ Np73 pathway





Figure 5.7

A possible signaling pathway regulating growth, differentiation and survival in neuroblastoma cells or sympathetic neurons. The NGF-triggered auto-phosphorylation of TrkA tyrosine kinase receptor induces activation of Ras/MAPK pathway, which in turn regulates nuclear pRB and Mdm2. In some poor-outcome neuroblastomas, p53, which is shuttling between cytosol and nucleus, is trapped in the cytosol by Parc, an anchoring protein of p53. MYCN induces expression of *Id-2* whose protein product in turn inhibits pRB. E2F1 negatively regulated by pRB directly induces expression of p73. p73 is regulated by Δ Np73 in a negative autoregulatory manner (Nakagawa et al. 2002), and Δ Np73 also inhibits p53



The importance of p53 and p73 has also been emphasized by the important observation that, in cultured neuroblastoma and other cancer cells, p73 directly transactivates the Δ Np73 gene by binding to its promoter after treating the cells with genotoxic reagents, e.g., cisplatin (Nakagawa et al. 2002). The induced Δ Np73 protein in turn interacts with either wild-type p53 or TAp73 and inhibits their proapoptotic function; thus, Δ Np73 can act as an oncogene and as an inhibitor of wild-type p53 and TAp73. The presence of this autoinhibitory feedback loop among p53, TAp73, and Δ Np73 may at least in part explain why there is no mutation of the p73 gene in cancers.

p53 is associated with TrkA via the proto-oncogene product c-Abl as an adaptor or bridging molecule, suggesting that it may also play a role in Trk signaling (Yano et al. 2000) (Fig. 5.7). The activation of Ras by NGF stimulation of the TrkA receptor induces p53 nuclear translocation and growth arrest in PC12 cells (Hughes et al. 2000). The c-Ha-Ras gene could be a target of p53, and protein products induce a positive feedback loop by activating p14^{ARF} which counteracts the negative feedback loop mediated by mdm2 (Deguin-Chambon et al. 2000). These observations strongly suggest that p53 and p73 tumor suppressors function in neurotrophin signaling and modulate the growth, differentiation, and apoptosis of neurons.

In neuroblastoma and some other human cancers, wild type p53 is often localized in the cytoplasm (Moll et al. 1995). Although the regulatory mechanism of cellular localization of p53 and p73 is still unknown, activated Ras in NGF/TrkA signaling stimulates the nuclear translocation of p53 and leads to growth arrest by the induction of p21^{WAF1} in PC12 cells (Hughes et al. 2000). Furthermore, some fractions of recurrent neuroblastomas and neuroblastoma cell lines acquire mutation of the p53 gene (Tweddle et al. 2001).

5.2.4 Apoptotic Signals in Neuroblastoma

To date, the spontaneous regression of neuroblastoma, has occurred only *in vivo*. Although this makes the analysis difficult, there are some important reports. An anti-apoptotic protein, Bcl-2, is expressed in primary neuroblastomas and neuroblastoma cell

lines. The expression levels of Bcl-2 and Bcl-X_L are high in aggressive tumor cells but are low in regressing cells (Ikeda et al. 1995; Ikegaki et al. 1995). Caspase-1 and caspase-3 are expressed at significantly higher levels in favorable neuroblastomas (Nakagawara et al. 1997), and caspase-8 is silenced in aggressive neuroblastomas by the methylation of its promoter as one of mechanisms (Teitz et al. 2000). Silencing of caspase-8 is observed in 25–35% of primary neuroblastomas with a high frequency in more aggressive tumors (Teitz et al. 2000; Eggert et al. 2001; van Noesel et al. 2003). Survivin, a member of the inhibitors of apoptosis protein (IAP), is mapped to the long arm of chromosome 17. In neuroblastoma, survivin is highly expressed in high-risk tumors, and its overexpression inhibits cellular apoptosis (Islam et al. 2000). Kitanaka et al. (2002) have recently reported an interesting observation that “autophagy” may be involved in the regression of neuroblastoma cells.

5.3 Conclusions

Development of neuroblastoma may be triggered by a genetic event(s) that leads to chromosome and/or the genomic DNA abnormalities such as amplification of the *MYCN* gene and deletions or gains in chromosomal regions including 1p, 11q, and 17q. Together with other epigenetic mechanisms of gene activation or gene silencing, they affect gene and protein expression which in turn deregulate cellular signaling. In neuroblastoma the normal biology of developing neuronal cells and cancer biology appear to overlap. A further understanding of the mechanisms involved in the transformation of progenitors or the stem cells into neuroblastoma with significant cellular heterogeneity may provide clues for the development of novel therapeutic strategies for this often aggressive lethal disease.

Acknowledgements. I thank M. Ohira and T. Ozaki for reading the manuscript. I also thank K. Yagyu for preparing the figures.

References

- Aloyz RS et al. (1998) p53 is essential for developmental neuron death as regulated by the TrkA and p75 neurotrophin receptors. *J Cell Biol* 143:1691–1703
- Altaba ARi, Stecca B, Sanchez P (2004) Hedgehog-Gli signaling in brain tumors: stem cells and paradevelopmental programs in cancer. *Cancer Lett* 204:145–157
- Axelsson H (2004) The Notch signaling cascade in neuroblastoma: role of the basic helix-loop-helix proteins HASH-1 and HES-1. *Cancer Lett* 204:171–178
- Azar CG, Scavarda NJ, Reynolds P, Brodeur GM (1990) Multiple defects of the nerve growth factor receptor in human neuroblastomas. *Cell Growth Differ* 1:421–428
- Ball DW (2004) Achaete-scute homolog-1 and Notch in lung neuroendocrine development and cancer. *Cancer Lett* 159–169
- Billon N et al. (2004) Roles for p53 and p73 during oligodendrocyte development. *Development* 131:1211–1220
- Boon K et al. (2001) N-MYC enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis. *EMBO J* 20:1383–1393
- Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM (1984) Amplification of N-MYC in untreated human neuroblastomas correlates with advanced disease stage. *Science* 224:1121–1124
- Canete A, Navarro S, Bermudez J, Pellin A, Castel V, Llombart-Bosch A (2000) Angiogenesis in neuroblastoma: relationship to survival and other prognostic factors in a cohort of neuroblastoma patients. *J Clin Oncol* 18:2789–2791
- Deguin-Chambon V, Vacher M, Jullien M, May E, Bourdon JC (2000) Direct transactivation of c-Ha-Ras gene by p53: evidence for its involvement in p53 transactivation activity and p53-mediated apoptosis. *Oncogene* 19:5831–5841
- Eggert A et al. (2000) Molecular dissection of TrkA signal transduction pathways mediating differentiation in human neuroblastoma cells. *Oncogene* 19:2043–2051
- Eggert A et al. (2001) Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. *Cancer Res* 61:1314–1319
- El-Badry OM, Helman LJ, Chatten J, Steinberg SM, Evans AE, Israel MA (1991) Insulin-like growth factor II-mediated proliferation of human neuroblastoma. *J Clin Invest* 87:648–657
- Enomoto H et al. (1994) Identification of human DAN gene, mapping to the putative neuroblastoma tumor suppressor locus. *Oncogene* 9:2785–2791
- Ernsberger U (2000) Evidence for an evolutionary conserved role of bone morphogenetic protein growth factors and phox2 transcription factors during noradrenergic differentiation of sympathetic neurons. Induction of a putative synexpression group of neurotransmitter-synthesizing enzymes. *Eur J Biochem* 267:6976–6981
- Guillemot F, Lo LC, Johnson JE, Auerbach A, Anderson DJ, Joyner AL (1993) Mammalian achaete-scute homolog 1 is required for the early development of olfactory and autonomic neurons. *Cell* 75:463–476
- Hamano S, Ohira M, Isogai E, Nakada K, Nakagawara A (2004) Identification of novel human neuronal leucine-rich repeat (hNLRR) family genes and inverse association of expression of Nbla10449/hNLRR-1 and Nbla10677/hNLRR-3 with the prognosis of primary neuroblastomas. *Int J Oncol* 24:1457–1466
- Hishiki T et al. (1998) Glial cell line-derived neurotrophic factor/neurturin-induced differentiation and its enhancement by retinoic acid in primary human neuroblastomas expressing c-Ret, GFR-1 and GFR-2. *Cancer Res* 58:2158–2165
- Huang EJ, Reichardt LF (2003) Trk receptors: roles in neuronal signal transduction. *Annu Rev Biochem* 72:609–642
- Huber K, Combs S, Ernsberger U, Kalcheim C, Unsicker K (2002) Generation of neuroendocrine chromaffin cells from sympathoadrenal progenitors: beyond the glucocorticoid hypothesis. *Ann NY Acad Sci* 971:554–559
- Hughes AL, Gollapudi L, Sladek TL, Neet KE (2000) Mediation of nerve growth factor-driven cell cycle arrest in PC12 cells by p53: simultaneous differentiation and proliferation subsequent to p53 functional inactivation. *J Biol Chem* 275:37829–37837
- Iavarone A, Lasorella A (2004) Id proteins in neural cancer. *Cancer Lett* 204:189–196
- Ichikawa M, Murakumo Y, Takahashi M (2004) RET and neuroendocrine tumors. *Cancer Lett* 204:197–211
- Ichimiya S et al (1999) p73 at chromosome 1p36.3 is lost in advanced stage neuroblastoma but its mutation is infrequent. *Oncogene* 18:1061–1066
- Ichimiya S, Nimura Y, Seki N, Ozaki T, Nagase T, Nakagawara A (2001) Down-regulation of *hASH1* is associated with the retinoic acid-induced differentiation of human neuroblastoma cell lines. *Med Pediatr Oncol* 36:132–134
- Ikeda H et al. (1995) Bcl-2 oncoprotein expression and apoptosis in neuroblastoma. *J Pediatr Surg* 30:805–808
- Ikegaki N, Katsumata M, Tsujimoto Y, Nakagawara A, Brodeur GM (1995) Relationship between bcl-2 and MYC gene expression in human neuroblastoma. *Cancer Lett* 91:161–168
- Islam A et al (2000) High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. *Oncogene* 19:617–623
- Kadomatsu K, Muramatsu T (2004) Midkine and pleiotrophin in neural development and cancer. *Cancer Lett* 204:127–143
- Kadomatsu K, Huang R-P, Sukanuma T, Murata F, Muramatsu T (1990) A retinoic acid responsive gene MK found in the teratocarcinoma system is expressed in spatially and temporally controlled manner during mouse embryogenesis. *J Cell Biol* 110:607–616

- Kawamoto T, Ohira M, Hamano S, Hori T, Nakagawara A (2003) High expression of the novel endothelin-converting enzyme genes, Nblao3145/ECEL1alpha and beta is associated with favorable prognosis in human neuroblastomas. *Int J Oncol* 22:815–822
- Kitanaka C et al (2002) Increased Ras expression and caspase-independent neuroblastoma cell death: possible mechanism of spontaneous neuroblastoma regression. *J Natl Cancer Inst* 94:358–368
- Klein R (1994) Role of neurotrophins in mouse neuronal development. *FASEB J* 8:738–744
- Klesse LJ, Parada LF (1999) Trks: signal transduction and intracellular pathways. *Microsc Res Tech* 45:210–216
- Kogner P, Barbany G, Dominici C, Castello MA, Raschella G, Persson H (1993) Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. *Cancer Res* 53:2044–2050
- Lasorella A, Nosedà M, Beyna M, Yokota Y, Iavarone A (2000) Id2 is a retinoblastoma protein target and mediates signalling by MYC oncoproteins. *Nature* 407:592–598
- Laurenzi VD et al. (2000) Induction of neuronal differentiation by p73 in a neuroblastoma cell line. *J Biol Chem* 275:15226–15231
- Li Y-S et al. (1990) Cloning and expression of a developmentally regulated protein that induces mitogenic and neurite outgrowth activity. *Science* 250:1690–1694
- Lo L, Morin X, Brunet JF, Anderson DJ (1999) Specification of neurotransmitter identity by Phox2 proteins in neural crest stem cells. *Neuron* 22:693–705
- Mac SM, D’Cunha CA, Farnham PJ (2000) Direct recruitment of N-MYC to target gene promoters. *Mol Carcinogr* 29:76–86
- Massari ME, Murre C (2000) Helix-loop-helix proteins: regulators of transcription in eukaryotic organisms. *Mol Cell Biol* 20:429–440
- Matsumoto K, Wada RK, Yamashiro JM, Kaplan DR, Thiele CJ (1995) Expression of brain-derived neurotrophic factor and p145^{TrkB} affects survival, differentiation, and invasiveness of human neuroblastoma cells. *Cancer Res* 55:1798–1806
- Moll UM, LaQuaglia M, Benard J, Riou G (1995) Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. *Proc Natl Acad Sci USA* 92:4407–4411
- Morin X, Cremer H, Hirsch MR, Kapur RP, Goridis C, Brunet JF (1997) Defects in sensory and autonomic ganglia and absence of locus coeruleus in mice deficient for the homeobox gene Phox2a. *Neuron* 18:411–423
- Nakagawa T et al (2002) Autoinhibitory regulation of p73 by ΔNp73 to modulate cell survival and death through p73-specific target element within the ΔNp73 promoter. *Mol Cell Biol* 22:2575–2585
- Nakagawara A (1998a) The NGF story and neuroblastoma. *Med Pediatr Oncol* 31:113–115
- Nakagawara A (1998b) Molecular basis of spontaneous regression of neuroblastoma: role of neurotrophic signals and genetic abnormalities. *Hum Cell* 11:115–124
- Nakagawara A (2001) Trk receptor tyrosine kinases: a bridge between cancer and neural development. *Cancer Lett* 169:107–114
- Nakagawara A (2004) Neural crest development and neuroblastoma: the genetic and biological link. In: Aloe L, Calza L (eds) NGF and related molecules in health and disease. Elsevier, Amsterdam, pp 233–242
- Nakagawara A, Arima M, Azar CG, Scavarda NJ, Brodeur GM (1992) Inverse relationship between trk expression and N-MYC amplification in human neuroblastomas. *Cancer Res* 52:1364–1368
- Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM (1993) Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. *N Engl J Med* 328:847–854
- Nakagawara A, Azar CG, Scavarda NJ, Brodeur GM (1994) Expression and function of TRK-B and BDNF in human neuroblastomas. *Mol Cell Biol* 14:759–767
- Nakagawara A et al. (1995) Differential expression of pleiotrophin and midkine in advanced neuroblastomas. *Cancer Res* 55:1792–1797
- Nakagawara A et al. (1997) High levels of expression and nuclear localization of ICE and CPP32 in favorable human neuroblastomas. *Cancer Res* 57:4578–4584
- Nakamura Y, Ozaki T, Koseki H, Nakagawara A, Sakiyama S (2003) Accumulation of p27^{KIP1} is associated with BMP2-mediated growth arrest and neuronal differentiation of human neuroblastoma-derived cell lines. *Biochem Biophys Res Commun* 307:206–213
- Oppenheim RW (1991) Cell death during development of the nervous system. *Annu Rev Neurosci* 14:453–501
- Pattyn A, Morin X, Cremer H, Goridis C, Brunet JF (1999) The homeobox gene Phox2b is essential for the development of autonomic neural crest derivatives. *Nature* 399:366–370
- Pozniak CD, Radinovic S, Yang A, McKeon F, Kaplan DR, Miller FD (2000) An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. *Science* 289:304–306
- Radtke F, Raj K (2003) The role of Notch in tumorigenesis: oncogene or tumour suppressor? *Nat Rev Cancer* 3:756–767
- Reale MA et al. (1996) Loss of DCC expression in neuroblastoma is associated with disease dissemination. *Clin Cancer Res* 2:1097–1102
- Rodriguez-Leon J, Merino R, Macias D, Ganan Y, Santesteban E, Hurler JM (1999) Retinoic acid regulates programmed cell death through BMP signalling. *Nat Cell Biol* 1:125–126
- Schneider C, Wicht H, Enderich J, Wegner M, Rohrer H (1999) Bone morphogenetic proteins are required in vivo for the generation of sympathetic neurons. *Neuron* 24:861–870
- Schwab M et al. (1983) Amplified DNA with limited homology to MYC cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. *Nature* 305:245–248

- Schwab M et al (1984) Chromosome localization in normal human cells and neuroblastomas of a gene related to *c-MYC*. *Nature* 308:288–291
- Schwab M et al. (2003) Neuroblastoma: biology and molecular and chromosomal pathology. *Lancet Oncol* 4:472–480
- Schweigerer L, Ledoux D, Fleischmann G, Barritault D (1991) Enhanced *MYCN* oncogene expression in human neuroblastoma cells is associated with altered FGF receptor expression and cellular growth response to basic FGF. *Biochem Biophys Res Commun* 179:1449–1454
- Seeger RC et al. (1985) Association of multiple copies of the *N-MYC* oncogene with rapid progression of neuroblastomas. *N Engl J Med* 313:1111–1116
- Shinbo J et al. (2002) p73-dependent expression of DAN during cisplatin-induced cell death and osteoblast differentiation. *Biochem Biophys Res Commun* 295:501–507
- Snider WD (1994) Functions of the neurotrophins during nervous system development: what the knockouts are teaching us. *Cell* 77:627–638
- Soderholm H et al. (1999) Human achaete-scute homologue 1 (*HASH-1*) is downregulated in differentiating neuroblastoma cells. *Biochem Biophys Res Commun* 256:557–563
- Stanke M, Junghans D, Geissen M, Goridis C, Ernsberger U, Rohrer H (1999) The *Phox2* homeodomain proteins are sufficient to promote the development of sympathetic neurons. *Development* 126:4087–4094
- Suzuki T, Bogenmann E, Shimada H, Stram D, Seeger RC (1993) Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. *J Natl Cancer Inst* 85:377–384
- Teitz T et al (2000) Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of *MYCN*. *Nat Med* 6:529–535
- Tian H, Hammer RE, Matsumoto AM, Russell DW, McKnight SL (1998) The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. *Genes Dev* 12:3320–3324
- Trochet D et al (2004) Germline mutations of the paired-like homeobox 2B (*PHOX2B*) gene in neuroblastoma. *Am J Hum Genet* 74:761–764
- Tweddle DA, Malcolm AJ, Bown N, Pearson AD, Lunec J (2001) Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. *Cancer Res* 61:8–13
- Van Noesel MM, Pieters R, Voute PA, Versteeg R (2003) The *N-MYC* paradox: *N-MYC* overexpression in neuroblastomas is associated with sensitivity as well as resistance to apoptosis. *Cancer Lett* 197:165–172
- Yamashiro D, Nakagawara A, Ikegaki N, Liu X, Brodeur GM (1996) Expression of *TRK-C* in favorable human neuroblastomas. *Oncogene* 12:37–41
- Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J, Vagner C, Bonnet H, Dikkes P, Sharpe A, McKeon F, Caput D (2000) p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. *Nature* 404:99–103
- Yano H, Cong F, Birge RB, Goff SP, Chao MV (2000) Association of the Abl tyrosine kinase with the Trk nerve growth factor receptor. *J Neurosci Res* 59:356–364
- Yoshida I, Koide S, Nakagawara A, Tsuji A, Matsuda Y (2001) Proprotein convertase *PACE4* is a target gene of the basic helix-loop-helix transcription factor *hASH-1*. *Biochem J* 360:683–689



Protein stability and function of p73 are modulated by a physical interaction with RanBPM in mammalian cultured cells

Sonja Kramer¹, Toshinori Ozaki¹, Kou Miyazaki¹, Chiaki Kato¹, Takayuki Hanamoto¹ and Akira Nakagawara^{*,1}

¹Division of Biochemistry, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuoh-ku, Chiba 260-8717, Japan

Upon a certain DNA damage including cisplatin treatment, p73 is stabilized and exerts its growth-suppressive and/or proapoptotic function. However, the precise molecular basis by which the intracellular levels of p73 are regulated remains unclear. In the present study, we have identified RanBPM as a novel binding partner of p73 α by yeast-based two-hybrid screening, and also found that RanBPM has an ability to stabilize p73 α . GST pull-down assays and co-immunoprecipitation experiments revealed that RanBPM directly bound to the extreme COOH-terminal region of p73 α , whereas it failed to interact with p53. Co-expression of RanBPM with p73 α resulted in the nuclear translocation of RanBPM, and both proteins co-localized in cell nucleus as examined by indirect immunofluorescent staining. It is worth noting that the expression of RanBPM inhibited the ubiquitination of p73 α , and thereby prolonged its half-life. Subsequent studies demonstrated that the proapoptotic activity of p73 α was significantly enhanced in the presence of RanBPM. Taken together, our present findings implicate a novel role for RanBPM in the regulation of p73 stability and function.

Oncogene (2005) 24, 938–944. doi:10.1038/sj.onc.1208257
Published online 22 November 2004

Keywords: p53; p73; RanBPM; two-hybrid; ubiquitination

p73 is a newly identified p53-related nuclear transcription factor, and functions to promote cell cycle arrest and/or apoptosis (Kaghad *et al.*, 1997). These cellular roles of p73 are largely attributed to its ability to transactivate specific target genes. In contrast to p53, p73 is expressed as multiple isoforms arising from either alternative splicing or alternative promoter usage (Melino *et al.*, 2002). Although functional differences among the splicing isoforms with different COOH-termini remain unclear, NH₂-terminally truncated forms of p73 (Δ Np73) have an oncogenic potential and exhibit a dominant-negative behavior toward wild-type p73 as

well as p53 (Pozniak *et al.*, 2000; Nakagawa *et al.*, 2002; Stiewe *et al.*, 2002).

Steady-state levels of p73 are kept extremely low under normal conditions, however, p73 is significantly induced at protein level in response to a certain genotoxic stress including cisplatin treatment, which is mediated by a nuclear nonreceptor tyrosine kinase c-Abl (Agami *et al.*, 1999; Gong *et al.*, 1999; Yuan *et al.*, 1999). c-Abl binds to the PXXP motif of p73 and phosphorylates p73 at Tyr-99. Alternatively, Ren *et al.* (2002) reported that protein kinase C δ catalytic fragment phosphorylates p73 at Ser-289, and increases its stability, suggesting that post-translational modification such as phosphorylation might contribute to increase the stability of p73. Protein phosphorylation has been shown to be involved in the initiation of protein ubiquitination by E3 ubiquitin ligase (Carrano *et al.*, 1999; Ganoth *et al.*, 2001). As described previously (Balint *et al.*, 1999; Lee and La Thangue, 1999), p73 is regulated at least in part by the protein degradation process through the ubiquitin–proteasome system. Additionally, Lee and La Thangue (1999) described that the COOH-terminal region of p73 α might have a regulatory role in the proteasome-dependent degradation of p73. Recently, we have found that MM1 and RACK1 interact with the extreme COOH-terminal region of p73 α , and regulate its transcriptional activity as well as proapoptotic function (Watanabe *et al.*, 2002; Ozaki *et al.*, 2003). However, these interactions did not have a detectable effect on the intracellular levels of p73 α .

To identify the possible cellular protein(s) involved in the regulation of p73 protein stability, we screened a cDNA library derived from human fetal brain using the extreme COOH-terminal region of p73 α (amino-acid residues 551–636) as a bait in a yeast-based two-hybrid system. After screening of approximately 5×10^5 transformants, 12 independent clones exhibited a high level of β -galactosidase activity, and subsequent sequence analysis revealed that three out of them encoded the overlapping regions of RanBPM (Figure 1a). RanBPM was initially identified as a cellular protein that can interact with Ran nuclear–cytoplasmic transport protein (Nakamura *et al.*, 1998; Nishitani *et al.*, 2001), and contained the putative SPRY domain which might be involved in protein–protein interactions (Ponting *et al.*, 1997). Although most of the Ran-binding proteins play an important role in nucleocytoplasmic transport, it is

*Correspondence: A Nakagawara;
E-mail: akiranak@chiba-ccri.chuo.chiba.jp
Received 16 July 2004; revised 4 October 2004; accepted 6 October 2004;
published online 22 November 2004